Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
about
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.Infliximab: 12 years of experienceFour-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid ArthritisRetrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature.Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.Economics of non-adherence to biologic therapies in rheumatoid arthritis.Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice.
P2860
Q34027648-F571504C-3438-4B1F-822E-21D59FAAE7D4Q34156535-F6A24A22-7360-487B-91B3-AEB87513DDDCQ35070446-74274AB9-83E3-49AB-BC94-0161C2B111CCQ35605643-92BDDA0B-8484-4D1F-9326-E50F018CC33DQ36480601-DEF4A774-1CCB-4E0B-BC27-7C9E1C4CF894Q36517701-736423C7-F879-45E8-93C2-672BFB394237Q37034034-B29EF803-6633-486C-963D-CC783A6D2507Q37108959-AE5C633D-6871-4B29-95EE-50CB32CB9E5DQ37473766-8E1B6322-670E-44A4-A263-CA9F3AE08252Q38250160-2D7D8D4C-AAC0-4E40-89A8-7F14666C2CD8Q46812628-296EBC15-95C6-48D6-AA2F-A2DF0CE08B01Q50964701-53676B88-D91A-493A-9E78-DC5378B6EA75
P2860
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@ast
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@en
type
label
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@ast
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@en
prefLabel
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@ast
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@en
P2093
P1433
P1476
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
@en
P2093
Anne Lohse
Eric Toussirot
Fabrice Michel
Gaelle Lehuede
Guewen-Edouard Materne
Jacques Massol
Marie-Christine Woronoff-Lemsi
P304
P356
10.1016/J.JBSPIN.2004.08.008
P577
2004-10-30T00:00:00Z